Novolizer Formoterol Meda (Formoterol Fumarate Dihydrate)

Novolizer Formoterol Meda is a LABA that acts on the bronchial smooth‑muscle pathway to improve airflow.

• Asthma: improves control of symptoms and reduces the frequency of bronchospasm episodes.
• Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases the need for rescue medication.
• Exercise‑induced bronchoconstriction: provides prophylactic bronchodilation for patients undertaking physical activity.

• Formoterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP. The rise in cAMP leads to relaxation of bronchial smooth muscle, producing a rapid and sustained bronchodilatory effect that persists for up to 12 hours.

Formoterol may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects

• Tremor: mild, transient shaking of the hands.
• Headache: dull or throbbing pain, often short‑lived.
• Throat irritation: discomfort or dryness in the throat after inhalation.
• Cough: brief episodes triggered by the powder inhaler.
• Palpitations: sensation of a rapid or irregular heartbeat.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of airway obstruction.
• Cardiovascular events: arrhythmia, angina, or myocardial ischaemia.
• Hypokalaemia: low blood potassium levels, potentially causing muscle weakness.
• Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Novolizer Formoterol Meda, clinicians should consider several safety aspects.

• Assess respiratory status: confirm diagnosis of asthma or COPD before initiation.
• Monitor cardiac function: patients with known heart disease should be observed for arrhythmias.
• Avoid overuse: limit use to the prescribed frequency to prevent tolerance.
• Review concomitant medications: check for other β2‑agonists or monoamine oxidase inhibitors.
• Educate on inhaler technique: ensure patients can correctly load and inhale the powder.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Formoterol can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may antagonise bronchodilatory effect and precipitate bronchospasm.
• Monoamine oxidase inhibitors (MAOIs): increase risk of cardiovascular stimulation.

Moderate Interactions (Monitor Closely)

• Other long‑acting β2‑agonists: additive bronchodilation may raise risk of tachycardia.
• Diuretics that cause hypokalaemia: may potentiate cardiac effects of β2‑agonism.
• Theophylline: concurrent use can enhance stimulant effects on the heart.